Pharmaceutical - Pharmaceutical, Hematology

Filter

Current filters:

PharmaceuticalHematology

Popular Filters

1 to 25 of 77 results

Helsinn gains exclusive rights to commercialize Pharmacosmos' Monofer in the USA

Helsinn gains exclusive rights to commercialize Pharmacosmos' Monofer in the USA

08-01-2015

Swiss oncology specialist Helsinn and Danish anemia drugmaker Pharmacosmos have entered into an agreement…

HelsinnHematologyLicensingMarkets & MarketingMonoferPharmaceuticalPharmacosmos

Shield Therapeutics' MAA for Ferracru accepted for review by EMA

Shield Therapeutics' MAA for Ferracru accepted for review by EMA

07-01-2015

Independent UK pharma company Shield Therapeutics has received acceptance for review of the Marketing…

FerracruHematologyPharmaceuticalRegulationShield TherapeuticsUK

Plasma fractionation market forecasts to 2019

06-01-2015

The global plasma fractionation market is witnessing continuous growth. The rise in aging population…

Baxter InternationalBio Product LaboratoryBiotestCSL LtdGlobalGrifolsHematologyKedrionLFB BiotechnologiesMarkets & MarketingOctapharmaPharmaceuticalSanquin

Daiichi Sankyo gets Japanese approval for Methylene Blue

05-01-2015

Japanese drug major Daiichi Sankyo has received approval in Japan for the manufacture and marketing of…

Daiichi SankyoHematologyJapanMethylene Blue InjectionPharmaceuticalProvepharmRegulation

Takeda ends partnership with AMAG Pharma on Rienso/Feraheme

Takeda ends partnership with AMAG Pharma on Rienso/Feraheme

30-12-2014

Japan’s largest drugmaker Takeda Pharmaceutical has entered into an agreement with US drugmaker AMAG…

AMAG PharmaceuticalsCanadaEuropeFerahemeHematologyLicensingNephrology and HepatologyPharmaceuticalRiensoTakeda Pharmaceutical

CSL Behring files BLA for hemophilia B agent

CSL Behring files BLA for hemophilia B agent

18-12-2014

USA-based CSL Behring, a unit of Australia’s CSL Ltd, has submitted a biologics license application…

CSL BehringCSL LimitedHematologyPharmaceuticalRegulationUSA

Positive new Ph III data for Novo Nordisk’s NovoEight in hemophilia A

08-12-2014

Danish diabetes major Novo Nordisk yesterday presented a new analysis of Phase III data demonstrating…

HematologyNovo NordiskNovoEightPharmaceuticalResearch

Bayer files for European approval of hemophilia A drug BAY 81-8973

06-12-2014

German pharma major Bayer has filed an application for marketing authorization to the European Medicines…

BAY 81-8973BayerEuropeHematologyPharmaceuticalRegulation

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

Sobi pays $10 million to exercise opt-in right for Elocta

Sobi pays $10 million to exercise opt-in right for Elocta

21-11-2014

Nordic biotech firm Swedish Orphan Biovitrum will exercise its opt-in right to take over final development…

Biogen IdecElocateEloctaFinancialHematologyPharmaceuticalSobiSweden

Positive early results for Boehringer Ingelheim’s investigational antidote idarucizumab

19-11-2014

The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study…

Boehringer IngelheimCardio-vascularHematologyidarucizumabPharmaceuticalPradaxaResearch

Par Pharmaceuticals receives FDA approval for Vasostrict in low blood pressure

Par Pharmaceuticals receives FDA approval for Vasostrict in low blood pressure

13-11-2014

Generic and branded specialty pharma company Par Pharmaceuticals has received approval for its New Drug…

HematologyPar PharmaceuticalsPharmaceuticalRegulationUSAVasostrict

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

Boehringer Ingelheim start Phase III trial on idarucizumab as antidote to Pradaxa

12-11-2014

German family-owned drug major Boehringer Ingelheim has initiated a global Phase III study on idarucizumab,…

Boehringer IngelheimHematologyidarucizumabPharmaceuticalPradaxaResearch

Highlights of EMA Pharmacovigilance unit meeting

09-11-2014

At its meeting last week, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

BayerBiogen IdecCSL BehringEuropeHelixateHematologyKogenateNeurologicalPharmaceuticalRegulationTecfidera

FDA study shows Pradaxa reduces stroke risk but raises chances of GI bleeding

FDA study shows Pradaxa reduces stroke risk but raises chances of GI bleeding

03-11-2014

A study carried out by the US Food and Drug Administration on Pradaxa (dabigatran etexilate mesylate)…

Boehringer IngelheimHematologyPharmaceuticalPradaxaRegulationResearchUSAWarfarin Sodium

FDA approves Baxter’s new treatment for rare form of hemophilia

FDA approves Baxter’s new treatment for rare form of hemophilia

25-10-2014

The US Food and Drug Administration on Friday approved Obizur (antihemophilic Factor [recombinant), porcine…

Baxter InternationalHematologyObizurPharmaceuticalRare diseasesUSA

CSL Behring to invest $450 million in capacity expansion

CSL Behring to invest $450 million in capacity expansion

08-10-2014

CSL Behring, a unit of Australia-headquartered CLS Limited, has today announced a multi-year, $450 million…

AlbuminAustraliaBehringCLS LimitedCSL BehringFinancialHealth Medical PharmaHematologyPharmaceuticalUSA

Perosphere and Daiichi Sankyo collaborate on Ph III study of PER977 with edoxaban

Perosphere and Daiichi Sankyo collaborate on Ph III study of PER977 with edoxaban

07-10-2014

USA-based Perosphere has entered into a third clinical trial collaboration agreement with Japanese pharma…

Cardio-vascularDaiichi SankyoedoxabanHematologyJapanPER977PerospherePharmaceuticalPortola PharmaceuticalsResearch

Avalon Ventures and GlaxoSmithKline launch two new companies

23-09-2014

Avalon Ventures today announced the launch of two new companies formed through its collaboration with…

Avalon VenturesFinancialGlaxoSmithKlineHematologyMergers & AcquisitionsPharmaceuticalRare diseasesSilarus TherapeuticsThyritope Biosciences

TG Therapeutics takes up option on PI3K-Delta inhibitor, TGR-1202

23-09-2014

US development stage company TG Therapeutics says it has exercised its option to license the global rights…

HematologyLicensingOncologyPharmaceuticalRhizen PharmaceuticalsTG TherapeuticsTGR-1202

Vifor appoints Dario Eklund head of international business and Abdul Mullick head of global marketing

Vifor appoints Dario Eklund head of international business and Abdul Mullick head of global marketing

19-09-2014

Swiss-based iron deficiency specialist Vifor Pharma has appointed Dario Eklund as head of international…

BoardroomHematologyPharmaceuticalSwitzerlandVifor Pharma

FDA backs added indication for GSK’s Promacta

FDA backs added indication for GSK’s Promacta

27-08-2014

The Food and Drug Administration has approved UK pharma giant GlaxoSmithKline’s supplemental New Drug…

GlaxoSmithKlineHematologyLigand PharmaceuticalsPharmaceuticalPromactaRare diseasesRegulationRevoladeUSA

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

21-08-2014

US drugmaker Baxter International has announced positive results from its Phase III pivotal clinical…

AdvateBAX 855Baxter InternationalHematologyPharmaceuticalRegulationResearch

1 to 25 of 77 results

Back to top